Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p.

Lublin 43 trials 18 recruiting

43 Registered trials

18 Currently recruiting

Organisation

Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p.

Location

Lublin, Poland

Identifier

ORG-100043218

Address

Ul. Polnocna 8/3, 20-064, Poland

Departments

#40702: N/A
Gastroenterology
n/a
N/D
NA
NA/ND
Neurology
Nie dotyczy
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p.
Niepubliczny Zakład Opieki Zdrowotnej Neuromed M. i M. Nastaj Sp. P.
Not applicable/Nie dotyczy
NZOZ Neuromed M. I M. Nastaj. sp.p.
unknown

Clinical trials at this site (43)

Search interface

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch… Recruiting

2024-512382-13-00 Migraine (with or without aura) 5 2022-10-04
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI… Ended

2023-505601-16-00 Chronic Migraine 5 2025-04-22
A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA) Ended

2024-517169-18-00 Multiple System Atrophy 5 2025-04-10
Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended

2023-508284-77-00 Generalized Myasthenia Gravis with autoantibodies again 5 2022-11-16
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514619-88-00 Relapsing Multiple Sclerosis 5 2022-03-18
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514618-11-00 Relapsing Multiple Sclerosis 5 2022-03-01
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended

2024-518364-12-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-09
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended

2024-512646-42-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2023-06-27
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Parkinson's Disease 4 2023-06-21
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-04-06
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended

2023-506975-83-00 HER2-positive metastatic breast cancer (MBC) and early 5
CHRONDI Ended

2024-513595-17-00 CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY 4